Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Edema Clinical Trial

Official title:
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Status Active, not recruiting

Clinical Trial Summary

This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back (recurrent), and who have achieved clinical response or stable disease to prior chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Clinical Trial Description

PRIMARY OBJECTIVES: Primary Objective: To assess the efficacy of MK-3475 as a single agent in patients with metastatic IBC or non-IBC TNBC EXPLORATORY OBJECTIVES: 1. To investigate the association between biomarkers in the peripheral blood and tumor tissue, such as PD-L1 expression, with safety and efficacy for IBC or non-IBC TNBC patients treated with MK-3475. 2. To determine the disease control rate of metastatic IBC or non-IBC TNBC patients who have achieved clinical response or stable disease to the systemic therapy. 3. To investigate the association between biomarkers and efficacy by RNA-sequencing of exosomes in blood and tumor for IBC or non-IBC TNBC patients treated with MK-3475. 4. To investigate the 5-year OS for IBC or non-IBC TNBC patients treated with MK-3475 OUTLINE: Patients receive pembrolizumab 200mg IV over approximately 30 minutes on day 1. Cycles repeat every 21 days for 8 cycles and then pembrolizumab 400mg IV every 42 days for total up to 24 months in the absence of disease progression or unacceptable toxicity After completion of study treatment, patients are followed up at approximately 1 and 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02411656
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 11, 2015
Completion date	December 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06003205` - Contributing Factors to Local Bioimpedance Spectroscopy	N/A
Completed	`NCT02055872` - Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial	Phase 3
Completed	`NCT01172522` - Topical Treatment of Under Eye Dark Circles and Swelling	Phase 2
Completed	`NCT00602615` - Bioequivalency Study of Torsemide Tablets Under Fed Conditions	N/A
Completed	`NCT00602303` - Bioequivalency Study of Torsemide Tablets Under Fasting Conditions	N/A
Completed	`NCT00115726` - Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure	Phase 4
Completed	`NCT04595448` - Lymphatic Function in Patients With Secondary Tricuspid Valve Regurgitation
Recruiting	`NCT06014203` - Examination of Edema After Arthroscopic Shoulder Surgery
Completed	`NCT06010394` - Control of Edema in the Knee in Patients With Knee Osteoarthritis	N/A
Recruiting	`NCT05310019` - Effect of Electroacupuncture in Patients Submitted Orthognathic Surgery and Mentoplasty	N/A
Recruiting	`NCT03442166` - Effectiveness of Light-emitting Diode (LED) Photobiomodulation in the Extraction of Retained Lower Third Molars	Phase 2
Completed	`NCT06220903` - The Effect of Complex Decongestive Therapy in Patients With Lymphedema	N/A
Withdrawn	`NCT03603990` - Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema	N/A
Recruiting	`NCT04927234` - Foot and Ankle Post-operative Oedema Management Using Geko™	N/A
Active, not recruiting	`NCT02876107` - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer	Phase 2
Recruiting	`NCT03704857` - Different Endodontic Treatment Techniques in Postoperative Symptoms, Apical Repair, Longevity of Rehabilitations, and Oral Health-related Quality of Life	N/A
Recruiting	`NCT04606030` - LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)	N/A
Completed	`NCT00732719` - Compression Device Safety Study on Edema	Phase 2
Not yet recruiting	`NCT05534308` - Effect of Intraoperative Taping on the Control of Edema Resulting From Stripping	N/A
Completed	`NCT04205253` - Tongue Depressor-related Ischemia-Reperfusion Injury in Tongue

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.